Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab

Alternative Splice Forms of VEGF in Colorectal Cancer - Possible Value in Anti-VEGF Therapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00897754

Enrollment

200

Registered

2009-05-12

Start date

2007-07-24

Completion date

2009-02-01

Last updated

2017-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

adenocarcinoma of the colon, adenocarcinoma of the rectum, recurrent rectal cancer, stage III rectal cancer, stage IV rectal cancer, recurrent colon cancer, stage III colon cancer, stage IV colon cancer

Brief summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to treatment. PURPOSE: This laboratory study is looking at gene expression in patients with advanced or metastatic colorectal cancer receiving bevacizumab.

Detailed description

OBJECTIVES: * Determine whether the balance of splice form expression alters susceptibility of tumors in vivo to respond to anti-VEGF therapy. OUTLINE: Tumor tissue samples collected on clinical trial E-3200 are analyzed for laboratory endpoints.

Interventions

GENETICgene expression analysis

GENETICprotein expression analysis

GENETICreverse transcriptase-polymerase chain reaction

OTHERimmunoenzyme technique

OTHERimmunohistochemistry staining method

OTHERimmunologic technique

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 120 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Tumor tissue samples available from patients with advanced or metastatic adenocarcinoma of the colon or rectum * Receiving bevacizumab on clinical trial E-3200 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

Measure	Time frame
Mean scores for VEGFb and pan-VEGF gene expression by IHC	1 month
Gene expression as measured by tissue microarrays	1 month
Splice form expression as measured by reverse transcriptase-PCR	1 month
VEGF165b protein expression as measured by ELISA	1 month

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026